Leerink Partners Issues Pessimistic Forecast for Abbott Laboratories (NYSE:ABT) Stock Price

Abbott Laboratories (NYSE:ABT) had its price target reduced by research analysts at Leerink Partners from $136.00 to $119.00 in a research report issued on Friday,MarketScreener reports. The brokerage presently has a “market perform” rating on the healthcare product maker’s stock. Leerink Partners’ price target indicates a potential upside of 8.86% from the stock’s current price.

Other equities research analysts also recently issued research reports about the company. Sanford C. Bernstein reduced their target price on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Royal Bank Of Canada cut their price target on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Daiwa Capital Markets lowered their target price on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a research note on Friday. Citigroup dropped their target price on Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating on the stock in a research report on Friday, January 23rd. Finally, Evercore ISI cut their target price on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $138.40.

Abbott Laboratories Stock Performance

Shares of ABT opened at $109.31 on Friday. The firm’s 50 day moving average price is $122.77 and its two-hundred day moving average price is $127.49. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70. Abbott Laboratories has a twelve month low of $105.27 and a twelve month high of $141.23. The firm has a market cap of $190.08 billion, a P/E ratio of 29.39, a PEG ratio of 1.69 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The company had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter in the prior year, the business earned $1.34 earnings per share. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Institutional Trading of Abbott Laboratories

Institutional investors have recently bought and sold shares of the stock. Norges Bank purchased a new stake in shares of Abbott Laboratories in the second quarter valued at $3,026,180,000. Laurel Wealth Advisors LLC raised its position in Abbott Laboratories by 13,347.0% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,056,934 shares of the healthcare product maker’s stock worth $823,804,000 after purchasing an additional 6,011,891 shares during the period. Invesco Ltd. lifted its position in shares of Abbott Laboratories by 51.0% during the third quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock worth $1,868,718,000 after purchasing an additional 4,713,135 shares during the last quarter. Vanguard Group Inc. grew its stake in Abbott Laboratories by 1.8% in the second quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock valued at $23,502,644,000 after purchasing an additional 2,977,715 shares during the last quarter. Finally, Ninety One UK Ltd purchased a new position in shares of Abbott Laboratories in the fourth quarter worth $336,815,000. 75.18% of the stock is currently owned by institutional investors.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.